334 related articles for article (PubMed ID: 34200555)
1. Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases.
Candelli M; Franza L; Pignataro G; Ojetti V; Covino M; Piccioni A; Gasbarrini A; Franceschi F
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200555
[TBL] [Abstract][Full Text] [Related]
2. Weak Agonistic LPS Restores Intestinal Immune Homeostasis.
Steimle A; Michaelis L; Di Lorenzo F; Kliem T; Münzner T; Maerz JK; Schäfer A; Lange A; Parusel R; Gronbach K; Fuchs K; Silipo A; Öz HH; Pichler BJ; Autenrieth IB; Molinaro A; Frick JS
Mol Ther; 2019 Nov; 27(11):1974-1991. PubMed ID: 31416777
[TBL] [Abstract][Full Text] [Related]
3. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
4. Metabolic endotoxemia promotes neuroinflammation after focal cerebral ischemia.
Kurita N; Yamashiro K; Kuroki T; Tanaka R; Urabe T; Ueno Y; Miyamoto N; Takanashi M; Shimura H; Inaba T; Yamashiro Y; Nomoto K; Matsumoto S; Takahashi T; Tsuji H; Asahara T; Hattori N
J Cereb Blood Flow Metab; 2020 Dec; 40(12):2505-2520. PubMed ID: 31910709
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I).
Chandran P; Satthaporn S; Robins A; Eremin O
Surgeon; 2003 Apr; 1(2):63-75. PubMed ID: 15573623
[TBL] [Abstract][Full Text] [Related]
6. Innate and adaptive immunity in inflammatory bowel disease.
Geremia A; Biancheri P; Allan P; Corazza GR; Di Sabatino A
Autoimmun Rev; 2014 Jan; 13(1):3-10. PubMed ID: 23774107
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota in the pathogenesis of inflammatory bowel disease.
Nishida A; Inoue R; Inatomi O; Bamba S; Naito Y; Andoh A
Clin J Gastroenterol; 2018 Feb; 11(1):1-10. PubMed ID: 29285689
[TBL] [Abstract][Full Text] [Related]
8. YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis.
Zhou X; Li W; Wang S; Zhang P; Wang Q; Xiao J; Zhang C; Zheng X; Xu X; Xue S; Hui L; Ji H; Wei B; Wang H
Cell Rep; 2019 Apr; 27(4):1176-1189.e5. PubMed ID: 31018132
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide and the gut microbiota: considering structural variation.
Mohr AE; Crawford M; Jasbi P; Fessler S; Sweazea KL
FEBS Lett; 2022 Apr; 596(7):849-875. PubMed ID: 35262962
[TBL] [Abstract][Full Text] [Related]
10. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
Stecher B
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
[TBL] [Abstract][Full Text] [Related]
11. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity.
Hersoug LG; Møller P; Loft S
Nutr Res Rev; 2018 Dec; 31(2):153-163. PubMed ID: 29362018
[TBL] [Abstract][Full Text] [Related]
12. How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology.
Frosali S; Pagliari D; Gambassi G; Landolfi R; Pandolfi F; Cianci R
J Immunol Res; 2015; 2015():489821. PubMed ID: 26090491
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk.
Manco M; Putignani L; Bottazzo GF
Endocr Rev; 2010 Dec; 31(6):817-44. PubMed ID: 20592272
[TBL] [Abstract][Full Text] [Related]
14. The interplay between microbes and the immune response in inflammatory bowel disease.
Goethel A; Croitoru K; Philpott DJ
J Physiol; 2018 Sep; 596(17):3869-3882. PubMed ID: 29806140
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease requires the interplay between innate and adaptive immune signals.
Shi D; Das J; Das G
Cell Res; 2006 Jan; 16(1):70-4. PubMed ID: 16467877
[TBL] [Abstract][Full Text] [Related]
16. Etiopathogenesis of inflammatory bowel disease: today and tomorrow.
de Souza HSP
Curr Opin Gastroenterol; 2017 Jul; 33(4):222-229. PubMed ID: 28402995
[TBL] [Abstract][Full Text] [Related]
17. Bacterial imbalance and gut pathologies: Association and contribution of E. coli in inflammatory bowel disease.
Khan S; Imran A; Malik A; Chaudhary AA; Rub A; Jan AT; Syed JB; Rolfo C
Crit Rev Clin Lab Sci; 2019 Jan; 56(1):1-17. PubMed ID: 30373492
[TBL] [Abstract][Full Text] [Related]
18. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
Imhann F; Vich Vila A; Bonder MJ; Fu J; Gevers D; Visschedijk MC; Spekhorst LM; Alberts R; Franke L; van Dullemen HM; Ter Steege RWF; Huttenhower C; Dijkstra G; Xavier RJ; Festen EAM; Wijmenga C; Zhernakova A; Weersma RK
Gut; 2018 Jan; 67(1):108-119. PubMed ID: 27802154
[TBL] [Abstract][Full Text] [Related]
19. Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.
Smolinska S; Groeger D; Perez NR; Schiavi E; Ferstl R; Frei R; Konieczna P; Akdis CA; Jutel M; OʼMahony L
Inflamm Bowel Dis; 2016 Jul; 22(7):1575-86. PubMed ID: 27271490
[TBL] [Abstract][Full Text] [Related]
20. Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease.
McDonnell M; Liang Y; Noronha A; Coukos J; Kasper DL; Farraye FA; Ganley-Leal LM
Inflamm Bowel Dis; 2011 Jan; 17(1):298-307. PubMed ID: 20806343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
